Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety

References

• KumarS, NyoduR, MauryaVK, SaxenaSK.Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). coronavirus disease 2019 (COVID-19). Coronavirus Dis. 2020:23–31. doi:10.1007/978-981-15-4814-7_3
   Google Scholar
• ChenY, LiuQ, GuoD. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. doi:10.1002/jmv.2568131967327
   PubMed Web of Science ®Google Scholar
• HoD, TsujiM. Infectious diseases: breakthroughs in developing vaccines, immune protective monitoring and measuring toxicity with functional proteomics. Isoplexis e-Book. 2020;3. Available from: https://isoplexis.com/literature/infectious-disease-breakthroughs-in-developing-vaccines-protective-immune-monitoring-measuring-toxicity/.
   Google Scholar
• BallP. The lightning-fast quest for COVID vaccines – and what it means for other disease. Nature. 2021;508:16–18. doi:10.1038/d41586-020-03626-1
   Web of Science ®Google Scholar
• RavichandranS, CoyleE, KlenowL, TangJ, GrubbsG, LiuS. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020;12(550):eabc3539. doi:10.1126/scitranslmed.abc353932513867
   PubMed Web of Science ®Google Scholar
• TsujiM, AkkinaR. Development of humanized mouse models for infectious diseases and cancer. Front Immunol. 2020. 10:3051. doi:10.3389/fimmu.2019.0305131998319
   PubMed Web of Science ®Google Scholar
• LeTT, AndreadakisZ, KumarA, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discovery. 2020;19:305–306. doi:10.1038/d41573-020-00151-832273591
   PubMed Web of Science ®Google Scholar
• PardiN, HoganMJ, PorterFW, WeissmanD. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discovery. 2018;17:261–279. doi:10.1038/nrd.2017.24329326426
   PubMed Web of Science ®Google Scholar
• ZhouX, JiangX, QuM, et al. Engineering antiviral vaccines ACS nano. ACS nano. 2020;1(14):12370–12389.
   Web of Science ®Google Scholar
• How mRNA vaccine works; 2021. Available from:https://youtube.com/watch?v=0vvygJ-vwo. Accessed 729, 2021.
   Google Scholar
• CoxRJ, BrokstadKA. Not just antibodies: b cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020;20(10):581–582. doi:10.1038/s41577-020-00436-432839569
   PubMed Web of Science ®Google Scholar
• Ninja Nerd lectures; 2020. Covid-19 vaccines: Moderna and Pfizer-BioNTech  Available from: http://wwwyoutube.com/watch?v=35ldbICU4o Accessed 729, 2021.
   Google Scholar
• DanJM, MateusJ, YuK, HastieK, FalitiCM, RamirezS. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv. 2021;371:6529. doi:10.1101/2020.11.15.383323;
   Google Scholar
• ZhenyuH, RenL, YangJ, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397(10279):1075–1084. doi:10.1016/S0140-6736(21)00238-533743869
   PubMed Web of Science ®Google Scholar
• McNeillMM, De StefanoF. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–472. doi:10.1016/j.jaci.2017.12.97129413255
   PubMed Web of Science ®Google Scholar
• ShimabukuroT, NairN. Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325(8):780–781. doi:10.1001/jama.2021.060033475702
   PubMed Web of Science ®Google Scholar
• WalshE, FrenckRW, FalseyAR, et al. Safety and Immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. doi:10.1056/NEJMoa202790633053279
   PubMed Web of Science ®Google Scholar
• Vaccine Pfizer data sheet; 2021.Fact sheet for healthcare providers administreting vaccines (vaccination providers) emergency use authorization (EUA) of Pfizer/BioNTech Covid 19 vaccine to prevent Coronavirus disease 2019 (Covid-19). Available from:https://www.fda.gov/media/144413/download. Accessed 729, 2021.
   Google Scholar
• Vaccine Moderna data sheet; 2020. Fact sheet for healthcare prividers administreting (EUA) of vaccines (vaccination providers) emergency use authorization of Moderna Covid-19 vaccine to prevent Coronavirus disease 2019 (Covid-19). Available from:https://www.fda.gov/media/144637/download. Accessed 729, 2021.
   Google Scholar
• SetteA, CrottyS.. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880. doi:10.1016/j.cell.2021.01.00733497610
   PubMed Web of Science ®Google Scholar
• PaiM, SchullM, RazakF, et al. Vaccine – induced prothrombotic immune thrombocytopenia (VIPIT) following AstraZeneca COVID-19 vaccination. Sci Briefs. 2020. http://covid19-sciencetable.ca/science-briefs.
   Google Scholar
• GreinacherA, ThieleT, WarkentinT, WeisserK, KyrleP, EichingerS. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination research square. Preprint April 7, 2021
   Google Scholar
• VilchesTN, ZhangK, VanER, LangleyJM, MoghadasSM. Projecting the impact of a two- dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine. 2021;39(17):2360–2365. doi:10.1016/j.vaccine.2021.03.05833812742
   PubMed Web of Science ®Google Scholar
• EmaryK, GolubchikT, AleyP, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351–1362. doi:10.1016/S0140-6736(21)00628-033798499
   PubMed Web of Science ®Google Scholar
• The Oxford/AstraZeneca COVID-19 vaccine: what you need to know; Updated March 17, 2021. from World Health Organization (WHO) Available from: https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know?gclid=Cj0KCQjw6s2IBhCnARIsAP8RfAj7JJxAKzNgcMEEpd2jng-5BmdtlwtVYJaRUbWD4C2IG5rxbXlu11UaAlZFE. Accessed 729, 2021.
   Google Scholar
• SuschakJ, WilliamsJA, SchmaljohnCS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccines Immunother. 2017;13:2837–2848. doi:10.1080/21645515.2017.1330236
   PubMed Web of Science ®Google Scholar
• Seheult R. (UC Riverside School of Medicine, University of California). Coronavirus update 121;Johnson and Johnson vaccine vs Pfizer and Moderna 2021. Available from: https://www.youtube.com/watch?v=13qT7wLxkvU&t=602s. Accessed 729, 2021.
   Google Scholar
• GrifoniA, WeiskopfD, RamirezS, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.32473127
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious disease (NIAID) and Pharmaceutical Janssen Companies from  the U.S. Department of Health and Human Services’:2021, February 29: Janssen investigational COVID-19 vaccine: interim analysis of phase 3 clinical data released. Available from:https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released. Accessed 729, 2021.
   Google Scholar
• Vaccine Janssen data sheet)2021. John Galloway (King's College London)  Available from: https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf. Accessed 729, 2021.
   Google Scholar
• JonesI, RoyP, SputnikV. COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642–643. doi:10.1016/S0140-6736(21)00191-433545098
   PubMed Web of Science ®Google Scholar
• LogunovD, DolzhikovaI, ShcheblyaKovD, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologos prime-boost COVID-19 vaccine: interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. doi:10.1016/S0140-6736(21)00234-833545094
   PubMed Web of Science ®Google Scholar
• Vaccine Novavax; 2021. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Accessed 729, 2021.
   Google Scholar
• HeathPT, GalizaEP, BaxterDN, BoffitoM, BrowneD, BurnsF. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New Engl J Med. 2021. doi:10.1056/NEJMoa2107659
   Web of Science ®Google Scholar
• Vaccine Reithera; March 18, 2021. Folgori A from INMI Spallanzani, Rome (Italy). Available from: https://reithera.com/2021/03/18/vaccino-anti-covid-19-al-via-la-seconda-fase-di-sperimentazione-di-reithera/?lang=it. Accessed 729, 2021.
   Google Scholar
• Vaccine Sinovac. 2021. from BBC news Avaialble from: https://www.bbc.com/news/world-asia-china-55212787. Accessed 729, 2021.
   Google Scholar
• JaraA, UndurragaEA, GonzálezC, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in chile. New Engl J Med. 2021. doi:10.1056/NEJMoa2107715
   Web of Science ®Google Scholar
• BuonaguroFM, AsciertoP, MorseG, et al. Covid-19: time for a paradigm change. Rev Med Virol. 2020;30(5):e2134. doi:10.1002/rmv.213432618072
   PubMed Web of Science ®Google Scholar
• E-Vax Italian vaccine. Available from:https://www.takisbiotech.it/index.php/news. Accessed 729, 2021.
   Google Scholar
• WodiAP, AultK, HunterP, McNallyV, SzilagyiPG, Henry BernsteinH. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger — United States, 2021.-. MMWR Morb Mortal Wkly Rep. 2021;70(6):189–192. doi:10.15585/mmwr.mm7006a133571172
   PubMed Web of Science ®Google Scholar
• Covid EU approves : Pfizer–BioNTech jab for 12-15 years old fromBBC news published May 28. 2021. Available from: https://bbc.com/news/world-europe-57287755.
   Google Scholar
• KimHW, JenistaER, WendellDC, et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021. doi:10.1001/jamacardio.2021.2828
   Web of Science ®Google Scholar
• DaganN, BardaN, KeptenE, MironO, PerchikS. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N England J M Ed. 2021;384:1412–1423. doi:10.1056/NEJMoa2101765ex51
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update. Stockholm: ECDC; 2021. Available from:https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update. Accessed 729, 2021.
   Google Scholar
• RambautA, LomanN, PybusO, et al. Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. 12, Report Superior sanity Institute (ISS). Bruno Kessler Foundation and Health Ministry; 2021.
   Google Scholar
• XieX, ZouJ, FontesGarfiasC, HongjieX, KenaAS, Cutler M et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited serra. BioRxiv. 2021. doi:10.1101/2021.01.07.425740
   Google Scholar
• LiuY, LiuJ, XiaH, XianwenZ, Fontes-GarfiasC. Neutralizing activity of BNT162b2-elicted serum. N Engl J Med. 2021;384:1466–1468. doi:10.1056/NEJMc210201733684280
   PubMed Web of Science ®Google Scholar
• NGS-SA Group Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant. N Engl J Med. 2021. doi:10.1056/NEJMoa2102214
   Web of Science ®Google Scholar
• RubinR. COVID-19 vaccines vs variants-determining how much immunity is enough. JAMA. 2021;325(13):1241–1243. doi:10.1001/jama.2021.337033729423
   PubMed Web of Science ®Google Scholar
• LipsitchM, Grad YH, SetteA, CrottyS. Cross-reactivity memory T cell and herd immunity to SARS-CoV-2. Nat Rev Immunol. 2020;20:709–713. doi:10.1038/s41577-020-00460-433024281
   PubMed Web of Science ®Google Scholar
• JalkanenP, KolehmainenP, HäkkinenHK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12:1. doi:10.1038/s41467-021-24285-433397941
   PubMed Web of Science ®Google Scholar
• AnthesE. The delta variant: what scientists know. in the New York Times; 2021.
   Google Scholar
• Venkata-ViswanadhE, PinskyBA, SutharM, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med. 2021. doi:10.1056/NEJMc2107799
   Web of Science ®Google Scholar
• EPR: UK launches clinical trial to study alternating COVID-19 vaccines for different doses; February 4, 2021. Rees V. from National Institute for Health Research (NIHR) in the UK  Available from: https://www.europeanpharmaceuticalreview.com/news/141736/uk-launches-trial-to-study-alternating-covid-19-vaccines-for-different-doses/. Accessed 729, 2021.
   Google Scholar
• Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891.33617777
   PubMed Web of Science ®Google Scholar
• BerkeleyL. One dose of Pfizer or Moderna vaccines was 80% effective in preventing Covid in CDC study of health workers. Health Sci. March 29, 2021. Available from: https://www.cnbc.com/2021/03/29/cdc-study-shows-single-dose-of-pfizer-or-moderna-covid-vaccines-was-80percent-effective.html.
   Google Scholar
• ManistyC, Otter AshleyD, TriebelT, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–1058. doi:10.1016/S0140-6736(21)00501-833640038
   PubMed Web of Science ®Google Scholar
• KrammerF, SrivastavaK, AlshammaryH, et al. Antibody responses in seropositive person after a single dose of SARS-CoV-2 mRNA vaccines. N Engl J Med. 2021;384:1372–1374. doi:10.1056/NEJMc210166733691060
   PubMed Web of Science ®Google Scholar
• SalimS, AbdoolK, De OliveiraT. New SARS-CoV-2 variants-clinical, public health, and vaccine implications. N Engl J Med. 2021. doi:10.1056/NEJMc2100362
   Web of Science ®Google Scholar
• GlaxoSmithKline clinical trial COMET-ICE (Covid-19 monoclonal antibody efficacy trial – intent to care early) study for the evaluation of VIR-7831; 2020. Landazabal F. from GSK S.p.A Available from:http://www.quotidianosanita.it/scienza-e-farmaci/articolo.php?articolo_id=88609. Accessed 729, 2021.
   Google Scholar
• SilveiraMM, MoreiraGMSG, MendonçaM. DNA vaccines against COVID-19: perspectives and challenges. Life Sci. 2021;267:118919. doi:10.1016/j.lfs.2020.11891933352173
   PubMed Web of Science ®Google Scholar
• Pfizer, BioNTech study 3rd booster of vaccine to protect against variants [dissertation] By The Science Advisory Board staff writers, February 25,2021. Available from: https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=2222https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=2222 . Accessed 729, 2021.
   Google Scholar
• Pfizer initiates phase 1 study of novel oral antiviral therapeutic agent against SARS-CoV-2; March 23, 2021. Elsele P. from Pfzer S p A Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral. Accessed 729, 2021.
   Google Scholar
• BlakneyA, McKayP. Next generation COVID-19 vaccines: here come the proteins. Lancet. 2021;39:643–644. doi:10.1016/S0140-6736(21)00258-0
   Web of Science ®Google Scholar
• LavineS, BjornstadO. Immunological characteristics govern the transition of COVID-19 endemicity. Science. 2021;371(6530):741–745. doi:10.1126/science.abe652233436525
   PubMed Web of Science ®Google Scholar